Overview

A class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws.  The Company’s common stock trades in an efficient market on the NASDAQ under the ticker symbol “SANA.”

The Sana class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Sana securities between March 17, 2023, and November 4, 2024, both dates inclusive (the “Class Period”).

Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system (“CNS”) disorders, and B-cell-mediated autoimmune diseases.  The Company’s product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of the Company’s fusogen platform for in vivo gene delivery for the treatment of hematologic malignancies.

Despite the attendant financial burden of developing numerous product candidates for a wide array of therapeutic areas, throughout the Class Period, Defendants repeatedly touted Sana’s financial wherewithal to maintain its current operations and advance its existing product candidates.  Simultaneously, Defendants consistently represented to investors that they were committed to financing and advancing SC291 (in oncology), SC379, and SG299.  For example, throughout the Class Period, Defendants repeatedly touted those product candidates’ purportedly promising preclinical and/or clinical results, upcoming data readouts, and regulatory events and timelines, including, inter alia, the preparation, submission, and/or approval of multiple investigational new drug applications with the U.S. Food and Drug Administration.

The Sana class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding Sana’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (2) SC291 in oncology, SC379, and SG299 were less promising than Defendants had led investors to believe; (3) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (4) accordingly, Defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired Sana securities between March 17, 2023, and November 4, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Sana class action lawsuit is May 20, 2025.